CEO Today - Healthcare Awards 2022

drug development, corporate development and pharmaceutical commercialization. Calliditas is also supported by its Scientific Steering Committee, a highly regarded network of leading experts, that serve as external advisors and investigators on clinical trials. At Calliditas, we are committed to being a responsible corporate citizen by constantly improving the ways in which our business activities have a social, environmental and economic impact. The foundation of our business is our drive to provide access to treatment for people with rare diseases with a high unmet medical need, and our commitment to the highest standard in business ethics is crucial in helping us to strive towards this goal. Calliditas is dedicated to providing a safe, stimulating, and encouraging environment for all our employees. Our success as a company is determined by our ability to operate as a unified team as we work to earn the trust and respect of our co-workers, investors, and ultimately our patients. Our company is built on a foundation of creative, productive and dedicated employees, and we are committed to ensuring that all have an equal opportunity to flourish and actively contribute to our overall mission. Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO® and conditional marketing authorization by the European Commission under the trade name KINPEYGO®. TARPEYO and Kinpeygo are the first and only treatments approved for IgA nephropathy by the FDA and EMA, respectively. Calliditas also has a pipeline in orphan-focused indications. Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas is led by an experienced and dedicated management team with an average of more than 15 years of prior experience in the pharmaceutical industry, including at leading companies such as GlaxoSmithKline, Pfizer and AstraZeneca. The board of directors includes highly qualified researchers, pharmaceutical sector executives and experts in Renee Aguiar-Lucander CEO of Calliditas Therapeutics AB CEO Today Hea l thcare Award s 2022 - SWEDEN - - 27 -

RkJQdWJsaXNoZXIy Mjk3Mzkz